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Letters
COMMENT & RESPONSE
Retinoids and Amyotrophic Lateral Sclerosis
To the Editor We read with great interest the article by Rosenbohm
and colleagues.1 They conducted a case-control study and re-
ported that retinol-binding protein 4 had an inverse associa-
tion with both risk for amyotrophic lateral sclerosis (ALS) and
disease prognosis. Although we agree with the relevance of
the reported results and their interpretation, we would like
to comment on 2 issues that might also correlate with these
findings.
First, as the authors indicated in the study, growing evi-
dence shows disturbances in energy metabolism levels in pa-
tients with ALS who may experience a shift from glucose to
lipid metabolism as the main energy source.2 Interestingly, ALS
is a very complex syndrome from a genotypic and pheno-
typic perspective. In this line, it has been postulated that causes
of the disease could vary depending on the clinical form.2 In
their article,1 Rosenbohm et al reported that 97 (33.6%), 91
(31.5%), and 73 (25.3%) of the patients had lumbar, bulbar, and
cervical onset, respectively, but they did not include this group-
ing category in the analysis of retinol-binding protein 4 levels.1
In our opinion, because some pathogenic features, as well as
several clinical conditions, such as diet, might differ between
bulbar and spinal ALS, it would have been interesting to have
considered this, for it would might provide further insight into
the pathogenesis of the different disease forms.
The second issue refers to the potential therapeutic role of
retinoids. Because of the absence of an effective modifying dis-
ease therapy, there is a pressing need to search for new thera-
pies for ALS. We previously showed that the retinoid agonist
bexarotene has clear neuroprotective associations in ALS mu-
rine models.3 Traditionally, there are important difficulties in
translating basic experimental findings into patients with ALS.4
However, the study by Rosenbohm et al1 provides further sup-
port for the implication of retinoids in ALS. Also, in line with this
concept, Nieves et al5 conducted a study to evaluate the asso-
ciation between nutrients and ALS course in more than 300
patients with ALS at the initial stages of the disease. Interest-
ingly, it was reported that patients who have carotene-
enriched diets exhibited a better prognosis.5 Altogether, these
studies suggest that retinoid pathway activation by bexarotene
or other retinoids might be considered in a clinical trial for pa-
tients with ALS.
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